SCHEMBL4924508

SCHEMBL4924508

Nc1nccc(-c2ccc(C(=O)NCc3cccc(C(F)(F)F)c3)s2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 5/20 0.51
DHFR P00374 1/20 0.51
ROCK1 Q13464 1/20 0.48
MLYCD O95822 1/20 0.47
ATG4B Q9Y4P1 2/20 0.47
MEN1 O00255 1/20 0.47
PLA2G1B P04054 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CCR1 P32246 2/20 0.46
AURKA O14965 1/20 0.45
RPS6KB1 P23443 1/20 0.45
AURKB Q96GD4 1/20 0.45
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14007256 0.88 MLYCD (0.51) DHFRMLYCDATG4BMEN1PLA2G1B
SCHEMBL4919234 0.87 AKT3 (0.57) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4925208 0.87 DYRK1A (0.56) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4930326 0.86 DYRK1A (0.55) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4925710 0.85 AKT3 (0.63) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4922539 0.85 AKT3 (0.53) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4919817 0.84 AKT3 (0.57) AKT3ROCK1CYP3A4LMNAHPGD
SCHEMBL4925722 0.84 AKT3 (0.55) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4922526 0.83 AKT3 (0.49) AKT3ROCK1DYRK1ADYRK1B
SCHEMBL4926954 0.82 ROCK2 (0.62) AKT3ROCK1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
EP-1708697-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-11-28 EP disclosed
EP-1708697-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 EP disclosed
WO-2005074642-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293716-A1 Chemical Compounds CYP11B2, CYP11B1, REN AKT3 1872/4885DHFR 903/4885ROCK1 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.